SYNI — Synvista Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$7.96m
- $0.05m
Annual income statement for Synvista Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2003 December 31st | C2004 December 31st | C2005 December 31st | 2006 December 31st | 2007 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K/A | 10-K/A | 10-K/A | 10-K |
| Standards: | — | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Other Revenue | |||||
| Total Revenue | 0 | 0.152 | 0.1 | 0.062 | 0.051 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15 | 14.7 | 13.4 | 17.9 | 9.96 |
| Operating Profit | -15 | -14.5 | -13.3 | -17.9 | -9.91 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -14.8 | -14.3 | -12.9 | -17.7 | -16.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.5 | -14 | -12.6 | -17.7 | -16.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.5 | -14 | -12.6 | -17.7 | -16.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -18.2 | -18.1 | -17.1 | -20.3 | -19.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -25.2 | -20.4 | -14.8 | -4.9 | -7.71 |
| Dividends per Share |